Investigational drug · Phase 3
RSVPreF3 OA vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus Infections.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
18
Any phase or sponsor naming "RSVPreF3 OA vaccine"
First trial start
2024
Aug 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSVPreF3 OA vaccine", any sponsor or status.
- Phase 315
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus Infections
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "RSVPreF3 OA vaccine" as an intervention, largest first.
- Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AbovePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04886596 · 26,675 participants · Start May 25, 2021 · Primary completion Apr 11, 2022
Drug: Placebo; RSVPreF3 OA vaccine · For: Respiratory Syncytial Virus Infections
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 277 sites in all
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06534892 · 10,212 participants · Start Aug 1, 2024 · Primary completion Sep 30, 2026
Drug: RSVPreF3 OA vaccine · For: Respiratory Syncytial Virus Infections
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 251 sites in all
- A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and OlderPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06551181 · 2,620 participants · Start Aug 5, 2024 · Primary completion Apr 24, 2025
Drug: RSVPreF3 OA investigational vaccine; Placebo (Saline solution) · For: Respiratory Syncytial Virus Infections
Sites: Shanghai, China; Espoo, Finland; Helsinki, Finland · 40 sites in all
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AbovePivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04732871 · 1,720 participants · Start Feb 15, 2021 · Primary completion Jun 6, 2022
Drug: RSVPreF3 OA investigational vaccine · For: Respiratory Syncytial Virus Infections
Sites: Mobile, Alabama; Phoenix, Arizona; Riverside, California · 46 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05590403 · 1,544 participants · Start Oct 28, 2022 · Primary completion Mar 13, 2023
Drug: RSVPreF3 OA investigational vaccine; Placebo · For: Respiratory Syncytial Virus Infections
GlaxoSmithKlineGSK (GSK)
NCT06389487 · 1,459 participants · Start Apr 29, 2024 · Primary completion Jul 29, 2024
Drug: RSVPreF3 OA investigational vaccine · For: Respiratory Syncytial Virus Infections
Sites: Glendale, Arizona; Phoenix, Arizona; North Hollywood, California · 52 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05879107 · 1,113 participants · Start May 26, 2023 · Primary completion Dec 6, 2023
Drug: RSVPreF3 OA investigational vaccine; PCV20 · For: Respiratory Syncytial Virus Infections
Sites: Guntersville, Alabama; Phoenix, Arizona; Huntington Beach, California · 38 sites in all
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and AbovePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05568797 · 1,045 participants · Start Oct 14, 2022 · Primary completion Feb 17, 2023
Drug: RSVPreF3 OA vaccine; FLU vaccine · For: Respiratory Syncytial Virus Infections
Sites: Edegem, Belgium; Erpent, Belgium; Genk, Belgium · 37 sites in all
- A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and AbovePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05559476 · 1,029 participants · Start Oct 20, 2022 · Primary completion Mar 7, 2023
Drug: RSVPreF3 OA investigational vaccine; FLU HD vaccine · For: Respiratory Syncytial Virus Infections
Sites: Birmingham, Alabama; Tempe, Arizona; Canoga Park, California · 46 sites in all
- A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and AbovePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04841577 · 976 participants · Start Apr 27, 2021 · Primary completion Sep 22, 2021
Drug: RSVPreF3 OA investigational vaccine; FLU-QIV · For: Respiratory Syncytial Virus Infections
Sites: Auckland, New Zealand; Christchurch, New Zealand; Havelock North, New Zealand · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in Italy.
Puggina A, Rumi F, Zarkadoulas E, et al. · Vaccines (Basel) 2025
- Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine.
Domnich A, Orsi A, Lai PL, et al. · Medicina (Kaunas) 2025
- Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Agedߙࣙߙ65.
Buynak R, Cannon K, DeAtkine D, et al. · Infect Dis Ther 2024
- Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.
Ferguson M, Murray A, Pliamm L, et al. · Vaccine X 2024
- The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ࣙ60ߙyears of age.
Curran D, Matthews S, Cabrera ES, et al. · Influenza Other Respir Viruses 2024
- The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ࣙ60 years in Japan: results of a Markov model analysis.
Kurai D, Mizukami A, Preckler V, et al. · Expert Rev Vaccines 2024
Also in development for Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccinePhase 33 trials
GSK · Respiratory Syncytial Virus Infections
- TNM001Phase 32 trials
Zhuhai Trinomab Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
- ZiresovirAK0529Phase 32 trials
Shanghai Ark Biopharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections, Respiratory Synctial Virus Infections
- Adjuvanted RSVPreF3 vaccinePhase 22 trials
GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections
- BLB-201PIV5-vectored RSV VaccinePhase 21 trial
Blue Lake Biotechnology Inc. · Respiratory Syncytial Virus Infections
- SYH2066Phase 21 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.